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Objective: Early identification of causative microorganism(s) in 
patients with severe infection is crucial to optimize antimicrobial 
use and patient survival. However, current culture-based patho-
gen identification is slow and unreliable such that broad-spec-
trum antibiotics are often used to insure coverage of all potential 
organisms, carrying risks of overtreatment, toxicity, and selection 
of multidrug-resistant bacteria. We compared the results obtained 
using a novel, culture-independent polymerase chain reaction/
electrospray ionization-mass spectrometry technology with those 
obtained by standard microbiological testing and evaluated the 
potential clinical implications of this technique.
Design: Observational study.
Setting: Nine ICUs in six European countries.
Patients: Patients admitted between October 2013 and June 
2014 with suspected or proven bloodstream infection, pneumonia, 
or sterile fluid and tissue infection were considered for inclusion.
Interventions: None.
Measurements and Main Results: We tested 616 bloodstream 
infection, 185 pneumonia, and 110 sterile fluid and tissue speci-
mens from 529 patients. From the 616 bloodstream infection 
samples, polymerase chain reaction/electrospray ionization-mass 
spectrometry identified a pathogen in 228 cases (37%) and cul-
ture in just 68 (11%). Culture was positive and polymerase chain 
reaction/electrospray ionization-mass spectrometry negative in 13 
cases, and both were negative in 384 cases, giving polymerase 
chain reaction/electrospray ionization-mass spectrometry a sensitiv-
ity of 81%, specificity of 69%, and negative predictive value of 97% 
at 6 hours from sample acquisition. The distribution of organisms 
was similar with both techniques. Similar observations were made 
for pneumonia and sterile fluid and tissue specimens. Independent 
clinical analysis of results suggested that polymerase chain reaction/
electrospray ionization-mass spectrometry technology could poten-
tially have resulted in altered treatment in up to 57% of patients.
Conclusions: Polymerase chain reaction/electrospray ionization-
mass spectrometry provides rapid pathogen identification in criti-
cally ill patients. The ability to rule out infection within 6 hours has 
potential clinical and economic benefits. (Crit Care Med 2015; 
43:2283–2291)
Key Words: critically ill; culture-independent; early diagnosis; 
infection; microbiology; molecular detection
The availability of rapid and reliable infectious dis-ease diagnostics that can provide results directly from patient specimens represents a major unmet need in 
managing critically ill patients. Current sepsis guidelines rec-
ommend initiation of IV antibiotic therapy as early as possible, 
ideally within the first hour (1), as any delay in effective anti-
microbial therapy may result in decreased survival (2). Effec-
tive therapy requires that the identity of causative pathogens 
and their resistance patterns are known. However, the cur-
rent standard-of-care, which depends on blood culture-based 
initial diagnosis, often takes at least 48–72 hours to provide a 
result. Furthermore, cultures often remain negative even when 
bacterial or fungal infections are strongly suspected (3), in 
part, related to concurrent antibiotic treatment (4).
Molecular diagnostic techniques that do not depend on 
growth of organisms in culture may offer a distinct advan-
tage over current methods. Most of the recently described 
molecular methods, however, rely on culture amplification as 
a precursor to diagnosis (5–8). Although these techniques may 
accelerate diagnosis for positive cultures, they do not address 
the significant proportion of false-negative cultures observed 
in patients with sepsis. In addition, many of these methods also 
use targeted pathogen detection with limited pathogen cover-
age such that negative results are often not highly predictive.
Polymerase chain reaction followed by electrospray ioniza-
tion-mass spectrometry (PCR/ESI-MS) can detect more than 
800 bloodstream infection (BSI)-relevant pathogens in a single 
assay and in approximately 6 hours (9–13). It can also identify 
three classes of antibiotic resistance markers associated with 
resistance to methicillin (mecA), vancomycin (vanA/vanB), 
and carbapenems (KPC). Using this technique, we recently 
demonstrated 83% sensitivity and 94% specificity compared 
with culture for direct detection of pathogens in whole-blood 
specimens from patients with suspected BSIs (13).
Here, we describe findings from the multicenter obser-
vational Rapid Diagnosis of Infections in the Critically Ill 
(RADICAL) study. The primary objective was to compare 
results obtained using the novel culture-independent PCR/
ESI-MS technology with those obtained from standard 
microbiological testing as a measure of clinical performance. 
Secondarily, to broadly address the clinical value of PCR/
ESI-MS detections, a panel of independent clinical adjudica-
tors was used to identify changes in patient management that 
may have occurred had the results from the PCR/ESI-MS 
technology been available for clinical use and assumed to be 
correct.
PATIENTS AND METHODS
All adult patients (≥ 18 yr) admitted between October 2013 
and June 2014 to one of nine ICUs in six European countries 
for the management of suspected or proven sepsis or severe 
infection were considered for inclusion in this prospective 
study. Ethical approval was obtained in each participating 
center. Informed consent was obtained from the patient or 
patient’s legal representative.
Patient Inclusion and Exclusion Criteria
Patients were considered for inclusion if they had 1) suspected or 
proven severe infection or sepsis and or 2) suspected or proven 
healthcare-associated pneumonia (HAP/HCAP), ventilator-
associated pneumonia (VAP), or severe community-acquired 
pneumonia (sCAP). Because pneumonia is the most common 
precipitating cause of sepsis, there may be an overlap between 
these two populations, but patients were included in one of the 
two groups, not both. Pneumonia (HAP/HCAP, VAP, and sCAP) 
was diagnosed in patients with an endotracheal tube in situ and 
a new infiltrate on chest radiograph plus temperature more than 
38°C or less than 35°C, increased sputum production, increased 
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or decreased WBC count (> 12 or < 4 cells/mL3), or a clinical 
suspicion of pneumonia, and the treating clinician expected the 
patient to still be intubated the next day.
The following exclusion criteria were used: the treating cli-
nician expected the patient to be discharged from the ICU on 
the day of evaluation or the following day, the treatment intent 
was palliative, the clinician was not committed to aggressive 
treatment, or death was deemed imminent and inevitable. 
Patients who had previously been included, but were read-
mitted to the ICU during the same hospitalization, were not 
included a second time.
Specimen Collection and Processing
Blood samples were collected whenever physicians ordered 
blood cultures because of clinical suspicion of a BSI, pneumo-
nia, or secondary site infection at a normally sterile site. Stan-
dard-of-care microbiology testing was performed according to 
usual practice in each institution. For testing using PCR/ESI-
MS, a minimum of 5-mL EDTA whole blood was drawn from 
the same venipuncture as for standard-of-care microbiology 
testing. An extra 5 mL was collected from an additional site 
whenever applicable. Lower respiratory tract (LRT) specimens 
from bronchoalveolar lavage (BAL) or endotracheal aspirate 
(ETA) were collected per standard clinical protocol, and ali-
quots used for PCR/ESI-MS testing. For sterile fluids and tis-
sues (SF&T), specimens tested included cerebrospinal (CSF), 
pleural, peritoneal, ascitic, or synovial fluid and surgical tissue/
biopsies. Urine samples were not considered. A minimum of 
0.5-mL fluid specimen or a minimum of 35-mg solid specimen 
was taken.
Specimens were cooled to 4°C within 30 minutes of collec-
tion and maintained at 4°C or frozen at –20°C until analysis. 
Genomic DNA was extracted from 5 mL of the EDTA-treated 
whole-blood clinical specimens as described previously (13). 
For other specimens (BAL, ETA, and other normally SF&T), 
total volume was brought up to 5 mL with buffered saline and 
processed as above. Eluates from the extraction were trans-
ferred into 16 wells (30 μL/well) of a custom polymerase 
chain reaction (PCR) assay strip prefilled (25 μL/well) with 18 
unique primer pairs and concentrated PCR master mix. The 
gene targets, primer sequences, and configuration have been 
described in detail previously (14). General PCR formulations 
and thermocycling conditions have also been described else-
where (10).
Clinical Data Collection
Orion Clinical Services (Berkshire, United Kingdom), a clinical 
research organization, provided electronic case report forms 
for collecting clinical data from enrolled patients. All pertinent 
patient data were de-identified and securely stored to maintain 
anonymity and confidentiality.
The following baseline data were collected upon enrol-
ment: patient demographics (e.g., age and sex), date and 
time of hospital and ICU admission, admission source (e.g., 
emergency department, outpatient clinic/referral, operating 
room, postanesthesia care unit, and other hospital unit), major 
comorbid conditions, immune status (immunosuppressed/
immunocompetent), site of suspected or confirmed infection, 
antimicrobial course prior to study enrolment, surgery/proce-
dures for suspected site of infection prior to enrolment, and 
Sequential Organ Failure Assessment Score (15).
Clinical data collected during admission included pertinent 
laboratory data, use of mechanical ventilation, and antimicro-
bial/antibiotic therapy including duration of therapy, and date 
therapy was initiated and discontinued. Vasoactive therapy, renal 
replacement therapy, surgical and other procedures for diagno-
sis/treatment of infection, radiological testing for diagnosis/
evaluation of potential infection, indwelling vascular access 
devices, and vital status at 28 days were also recorded. Discharge 
data included date of discharge (ICU and hospital), discharge 
destination (general hospital floor, skilled nursing facility, and 
home), and vital status at discharge (survival/death).
Specimen Data Collection
The following specimen-related data were recorded: specimen 
type (whole blood, body fluid, tissue, BAL, and ETA); date 
and time of collection for each specimen taken for use with 
PCR/ESI-MS; total amount of fluid collected; sample handling 
and storage; standard-of-care microbiological test results for 
specimens taken concurrently; time to obtain positive results 
(and or determination of negative results) for standard-of-care 
microbiological testing; data for secondary objectives and to 
adjudicate potential discrepant results; recent microbiologi-
cal testing within prior 30 days (if available); and additional 
microbiological testing following enrolment in study until 
hospital discharge.
Sample Size
This exploratory study was not statistically powered. We 
estimated that approximately 500 patients would have to be 
enrolled to enable a reasonable assessment of the performance 
of the PCR/ESI-MS suite of assays when compared with stan-
dard-of-care microbiology.
Data Analysis
Results obtained with the PCR/ESI-MS technology for each 
specimen were compared with those obtained using conven-
tional microbiology methods for the same sample. If multiple 
specimens were taken from a patient per standard-of-care pro-
tocols, each was independently analyzed in this study. Agree-
ment and concordance were assessed using a McNemar test 
(16) and Cohen κ (17). All percentages and CIs for proportions 
were calculated using the exact method and are rounded to the 
nearest percentage. Direct comparison of positive and negative 
results was conducted with organism identification for each 
method (conventional microbiology vs PCR/ESI-MS) for each 
specimen type. Coagulase-negative staphylococcus and other 
common skin contaminants were annotated as “potential con-
taminants” for both methods and excluded from the overall 
analysis, as previously described (13).
Discrepant results between the PCR/ESI-MS and culture 
cannot be directly confirmed by an independent method, as 
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previously described (13). Two approaches were used to resolve 
discrepancies. In a subset of patients, multiple samples were 
collected per standard-of-care. This included two indepen-
dent fresh venipunctures (left arm vs right arm) or one veni-
puncture plus one sample collected from an indwelling line. 
Paired analysis of PCR/ESI-MS testing results between these 
independently collected samples was conducted to indicate the 
likelihood of true infection. In addition, independent clinical 
adjudication (described below) was performed using all the 
clinical data collected as part of the study, including standard-
of-care microbiology results and PCR/ESI-MS results.
All statistical tests were performed using SAS version 
9.3 (SAS Institute, Cary, NC) or Minitab16 (Minitab, State 
College, PA). A p value of less than 0.05 was considered statisti-
cally significant.
RESULTS
Of 543 patients enrolled in the study, 14 did not have match-
ing PCR/ESI-MS or standard-of-care microbiology results 
and were excluded from the final analysis. Table 1 shows the 
patient demographics, reflecting a typically heterogeneous 
ICU population: one third of the patients were admitted from 
the emergency department; 75% were exposed to one or more 
antibiotics prior to study enrolment. Overall mortality was 
29%, with cardiac arrest, septic shock, multiple organ failure, 
and acute respiratory distress syndrome accounting for ~62% 
of deaths.
BSI Analysis
A total of 616 direct whole-blood specimens from the 529 
patients were tested to assess the accuracy of organism iden-
tification. PCR/ESI-MS results from analysis of blood using 
the bacteria, antibiotic resistance, and Candida BSI assay 
were compared with results from standard clinical micro-
biology cultures. As shown in Table 2, there were 228 PCR/
ESI-MS positive specimens (36.5%) for at least one pathogen 
compared with 68 positive specimens by culture (10.9%). 
The total number of positive tests for each method was sta-
tistically different (McNemar test statistic = 137.6; df = 1; 
p < 0.0001). There were 55 samples that were positive for 
the same organism with both techniques (Table 2), yielding 
an overall concordance of identification (calculated sensitiv-
ity) of 81% (95% CI, 70–89%) and a κ value of 0.25 (95% 
CI, 0.18–0.31). In 13 instances, culture identified an organ-
ism that was either negative by PCR/ESI-MS (6/13) or the 
identity of the organism reported by PCR/ESI-MS did not 
match the organism identified by microbiology testing (7/13) 
(Table S1, Supplemental Digital Content 1, http://links.lww.
com/CCM/B418). In contrast, PCR/ESI-MS reported a BSI-
relevant organism in 173 additional specimens that were cul-
ture negative, resulting in a calculated assay specificity of 69% 
(Table S2, Supplemental Digital Content 1, http://links.lww.
com/CCM/B418). Finally, there were 384 concordant nega-
tive specimens, yielding a negative predictive value (NPV) of 
~97% (95% CI, 94–98%).
The frequencies of organisms detected from BSI speci-
mens are shown in Figure 1. The distributions of the top 10 
species detected by microbiology and those detected by PCR/
ESI-MS were similar. The largest single discrepancy between 
the two methods by sheer volume of detections was in the 
identification of Escherichia coli. Although culture and PCR/
ESI-MS techniques both reported E. coli as the most abun-
dant species, PCR/ESI-MS detection was 4-fold higher (89 vs 
21). Other organisms in which blood culture performed less 
well included the enterococcus species, Enterococcus faecalis 
(1 vs 10) and Enterococcus faecium (2 vs 25), Candida albicans 
(2 vs 13), and Staphylococcus aureus (14 vs 31). In contrast, 
Pseudomonas aeruginosa detection was comparable between 
the two methods (6 vs 8). Additional analysis of the PCR/
ESI-MS results showed that the levels (genome equivalent/
mL) of organisms reported in the majority of these PCR/
ESI-MS positive, but culture-negative, cases were similar to 
cases in which culture matched PCR/ESI-MS detections (data 
not shown).
TABLE 1. Patient Demographics and 
Baseline Clinical Characteristics
Mean age, yr 61.0 ± 17.9
Sex, % 35.4 (female)/ 
64.6 (male)
Admission source, %
  Emergency department 31.5
  Outpatient 2.1
  Operating room 15.6
  Other hospital ward 25.3
  Postanesthetic care unit 1.0
  Other 18.9
Immune status, %
  Immunocompetent 83.4
  Immunosuppressed 16.6
Antimicrobial use, %
  Within 30 d prior to hospitalization 12.7
  Initiated during hospitalization but 
before enrolment
62.7
  Initiated at or after enrolment 22.1
Major comorbidities, %
  Hypertension 44.5
  Cardiac (myocardial infarction/
congestive heart failure)
26.4
  Diabetes mellitus 23.1
  Cancer/neoplastic disease 19.1
Mean Sequential Organ Failure 
Assessment score
7.6 + 4.2
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When subsets of specimens were tested in replicate using 
independently collected samples, 52 of 168 replicate samples 
were positive in both PCR/ESI-MS tests (Table S3, Supplemental 
Digital Content 1, http://links.lww.com/CCM/B418). In con-
trast, culture was positive in the two replicates in only 12 of 158 
samples, all of which were also PCR/ESI-MS positive in both 
samples. In three instances, culture was positive in one of two 
replicates and was negative by PCR in both samples tested (false 
negative by PCR), whereas in three and four cases, respectively, 
when culture was positive in one replicate, PCR was positive in 
one or both replicates (Table S4, Supplemental Digital Content 
1, http://links.lww.com/CCM/B418).
Nonbloodstream Infections
Heterogeneous samples from patients with suspected pneu-
monia or sterile site infections were also obtained in several 
cases. Overall, there were 185 LRT samples (88 BAL, 96 ETA, 
and 1 other) and 110 SF&T samples (36 intraperitoneal fluid, 
14 pleural fluid, 11 CSF, 13 tissue, and 36 other fluid types). 
Results from the analysis of these specimens are shown in 
Table 3. LRT and SF&T specimens often had multiple detec-
tions reported by both methods in several samples. Only the 
primary detections by either method were included in the 
analysis. The overall sensitivities for concordance between 
standard-of-care and PCR/ESI-MS were 84% (95% CI, 74–
91%) and 85% (95% CI, 72–93%), respectively. As for the 
bloodstream infection data, the McNemar test for both the 
LRT and the SF&T sample data showed that the total number 
of samples considered positive was significantly different for 
culture versus PCR/ESI-MS (McNemar test statistic = 20.9 for 
LRT and 15.2 for SF&T; p < 0.0001 in both cases). Also similar 
to the bloodstream infection data, there was more agreement 
in the contingency table comparing culture to PCR/ESI-MS 
than would be expected by chance (LRT κ = 0.35; 95% con-
fidence limits, 0.23, 0.47 and SF&T κ = 0.27; 95% confidence 
limits, 0.11, 0.43). For LRT specimens, there was no statisti-
cally significant difference in sensitivity (p = 0.677) or speci-
ficity (p = 0.444) when testing the hypothesis that the BAL 
proportion – the ETA proportion was equal to zero.
In 151 patients, two or more specimen types (BSI plus 
LRT and/or SF&T) were obtained and analyzed. In 86 of 
these 151 cases (57%), the same organisms were reported by 
PCR/ESI-MS in all samples tested from an individual patient 
(data not shown). In comparison, culture concordance 
between the sample types was seen in only 19 cases (12%), 
driven largely by no detection reported in the BSI culture 
results.
Resistance Markers
There were no identified cases of Klebsiella-associated carbapen-
emase. There was a single report of vancomycin-resistant Entero-
cocci, which was matched across the two methods. There were 23 
reports of mecA+ staphylococcus organisms (seven in BSI sam-
ples, 13 in LRT samples, and three in SF&T samples), with the 
following agreement between PCR/ESI-MS and culture: for BSI 
samples, results were concordant in four cases, and PCR/ESI-
MS was positive and culture negative in three; for LRT samples, 
results were concordant in three cases, PCR/ESI-MS was posi-
tive with culture negative in nine, and PCR/ESI-MS was negative 
with culture positive in one; and the three cases in the SF&T 
samples were concordant across PCR/ESI-MS and culture.
Clinical Value Assessment
To assess the clinical significance of the PCR/ESI-MS detec-
tions, each case was adjudicated by a panel of three indepen-
dent clinical expert reviewers randomly selected from a pool 
of seven infectious disease, microbiology, and intensive care 
specialists not associated with the study sites. The panel was 
provided with clinical case summaries, and PCR/ESI-MS 
results and standard-of-care results from all samples tested. To 
identify potential changes in antimicrobial management that 
may have occurred if the results from the PCR/ESI-MS tech-
nology had been available for clinical use, the panel was pro-
vided with a questionnaire (Table 4). Analysis of the reviewers’ 
independent responses was performed using a majority rule 
such that two of three responses for a given patient determined 
the outcome for that patient. Table 4 provides a breakdown 
of the responses by each question. Combining all responses 
per patient and eliminating overlapping answers so that only 
a single response was recorded per patient gave an overall rec-
ommendation for change based on PCR/ESI-MS compared 
with standard-of-care in 178 patients (41%). This percentage 
increased to 57% for cases in which PCR/ESI-MS results were 
positive and microbiology results were negative.
DISCUSSION
The important findings of the RADICAL study are that PCR/
ESI-MS detected BSI pathogens with high overall sensitivity 
and NPV; PCR/ESI-MS was three times more likely to identify 
TABLE 2. Bloodstream Infection Assay Performance
Culture
+ – Total Sensitivity 81% (95% CI, 70–89%)
Polymerase chain reaction/ 
electrospray ionization-mass 
spectrometry
+ 55 173 228 Specificity 69% (95% CI, 65–73%)
– 13 384 397 Positive predictive 
value
24% (95% CI, 19–30%)
Total 68 557 625 Negative predictive 
value
97% (95% CI, 94–98%)
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Figure 1. Bacteria and Candida detected in the Rapid Diagnosis of Infections in the Critically Ill (RADICAL) study. Distribution of organisms reported by 
polymerase chain reaction/electrospray ionization-mass spectrometry (PCR/ESI-MS) (blue bar) and culture (red bar) observed in the RADICAL study 
are shown, sorted by decreasing order of PCR/ESI-MS reported organisms. Both methods showed similar distribution for the top eight reportable organ-
isms that were seen >5 times by PCR/ESI-MS, with some minor reshuffling of the order. PCR/ESI-MS showed a longer tail of reportable organisms that 
were infrequent (≤5 times). Normal skin flora are shown below the line were not included in further analysis by either method.
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an organism than standard culture; and, if available, PCR/ESI-
MS results may have altered the treatment regimen in as many 
as 57% of patients.
Sepsis affects a large proportion of the critically ill popu-
lation. Despite improvements in recent years, morbidity and 
mortality rates remain high (18). The importance of initiating 
treatment as soon as possible has been highlighted and shown 
to be associated with improved outcomes (2), yet this finding 
needs to be balanced against the direct risks and stewardship 
issues arising from overzealous or inappropriate antibiotic use.
Rapid diagnosis of severe infection or sepsis is thus crucial not 
only to optimize a patient’s chances of survival but also to encour-
age responsible antibiotic use. However, diagnosing infection 
accurately in critically ill patients is challenging. Characteristic 
clinical and laboratory signs of severe infection, such as tachycar-
dia, fever, and altered WBC count, are nonspecific and are often 
present in other acute conditions. Biomarkers, such as C-reactive 
protein and procalcitonin, are also nonspecific and are of more 
value in ruling out infection than in making a definite diagnosis 
(19). Microbiological culture results are negative in many patients 
with sepsis, largely because prior antimicrobial therapy affects ex 
vivo growth in culture medium (1). Certain microorganisms are 
also particularly difficult to culture, requiring specific growth 
media or a particular environment. As culture results often 
require several days to become available, patients with suspected 
severe infection are, therefore, often started on empiric broad- 
spectrum antibiotics to increase the likelihood that a pathogenic 
organism will be adequately covered. This approach, although 
valid in terms of preventing delays in starting treatment with 
currently available diagnostic techniques, has several negative 
aspects, including the potential for toxicity with multiple antibi-
otics, the high-associated costs, and the effects of antibiotic pres-
sure on the development of antimicrobial resistance (20).
Availability of a technique that could provide more 
rapid pathogen identification directly from patient samples 
could, therefore, represent a marked improvement in terms 
of enabling more rapid diagnosis and earlier initiation of 
appropriate antimicrobial therapy, with associated beneficial 
effects on outcomes, antimicrobial resistance, costs, and tox-
icity. Various methods have been suggested for this purpose, 
including single pathogen assays, which are of limited use in 
patients with suspected sepsis in whom multiple organisms 
may be involved; selected-pathogen assays, which use specific 
molecular targets to identify some 20–35 species (21–23); and 
broad-range pathogen assays, which use universal or conserved 
targets to identify many hundreds of species, but for which 
TABLE 3. Assay Performance in Samples From Lower Respiratory Tract and Sterile Fluid 
and Tissue Infections
Culture
Lower respiratory tract + – Total Sensitivity 84% (95% CI, 74–91%)
  PCR/ESI-MS + 68 49 117 Specificity 53% (95% CI, 43–63%)
– 13 55 68 PPV 58% (95% CI, 40–67%)
Total 81 104 185 NPV 81% (95% CI, 70–89%)
Sterile fluid and tissue + – Total Sensitivity 85% (95% CI, 72–93%)
  PCR/ESI-MS + 45 33 78 Specificity 42% (95% CI, 29–56%)
– 8 24 32 PPV 58% (95% CI, 46–69%)
Total 53 57 110 NPV 75% (95% CI, 57–89%)
PPV = positive predictive value, NPV = negative predictive value.
TABLE 4. Clinical Value Adjudication by Independent Reviewers
Reviewer Questions Numbers of “Yes” Votes Percent of Total
1. On receipt of the PCR/ESI-MS results would you narrow the 
patient’s antimicrobial regimen?
66 15
2. On receipt of the PCR/ESI-MS results would you expand the 
antimicrobial regimen?
46 11
3. Would the PCR/ESI-MS results trigger you to shorten or 
discontinue the antimicrobial regimen?
49 11
4. Would the PCR/ESI-MS results trigger you to initiate antibiotic 
therapy (applies to cases where the patient was not on antibiotic 
therapy at the time the culture/PCR/ESI-MS sample was drawn)?
80 18
5. Would you alter, institute, or cease antibiotic therapy earlier? 148 34
PCR/ESI-MS = polymerase chain reaction/electrospray ionization-mass spectrometry.
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earlier versions lacked sensitivity due to the small volumes of 
blood extracted for analysis (24, 25).
The PCR/ESI-MS test used in RADICAL can detect more 
than 800 bacterial and candida species from a single 5-mL EDTA 
blood sample, with results available within 6 hours from when 
the sample enters the testing laboratory. This is much faster than 
standard culture techniques that frequently take 48–96 hours 
for full identification with susceptibility profile. As expected, 
the PCR/ESI-MS assay identified significantly more positive 
samples than standard culture, possibly because it does not rely 
on bacterial growth and thus can identify organisms even in the 
presence of ongoing antimicrobial therapy. In the present study, 
over 75% of the patients were exposed to antibiotic treatment 
prior to enrolment (Table 1). This may explain in part the sig-
nificant lack of microbiological growth in a large number of the 
PCR/ESI-MS positive cases. The simple κ statistic was used to 
estimate the agreement between culture and PCR/ESI-MS, but 
it underrepresents this agreement because of the requirement 
that the PCR/ESI-MS assay and blood culture results matched 
in terms of organism identity in order to be considered a true 
positive in the contingency table. The data were simplified and 
samples categorized as either an organism match or no match; 
hence, all organism agreement can be considered as being 
unlikely to have happened by chance. Furthermore, the paucity 
(< 1–10) of microbial colony-forming units/mL of blood, as 
reflected by higher culture yields through taking large volumes 
of blood (26–28), could be expected to significantly increase the 
risk of a false-negative result with a 20-mL blood sample. Despite 
this, the PCR/ESI-MS and culture methods both showed similar 
agreement on replicate testing using the κ statistic.
Importantly, in 41% of cases, the panel of independent 
experts would have recommended a change in management, 
including initiation of therapy, altered antimicrobial spec-
trum, and/or change in duration of therapy, based on the PCR/
ESI-MS results. This percentage increased to 57 when PCR/
ESI-MS tests were positive.
This study has several limitations. First, PCR/ESI-MS can-
not provide detailed antimicrobial susceptibility information, 
unlike culture techniques. Hence, although it can provide 
sensitive and rapid identification of causative microorgan-
isms, PCR/ESI-MS cannot currently replace culture methods. 
The results reported here need to be confirmed in studies that 
can directly determine the impact of this approach on clinical 
and economic outcomes, including length of stay and sur-
vival, but also on resistance patterns.
Second, the greater detection rate of E. coli, S. aureus, E. fae-
cium, C. albicans, and Klebsiella pneumoniae by PCR/ESI-MS 
compared with routine culture was unanticipated, and the 
explanation is unclear. Prior to study inclusion, most patients 
were exposed to combinations of two or more antibiotics active 
against Gram-positive and Gram-negative organisms and were 
often receiving one or more antifungals in addition. As stated 
above, the bacterium/fungus may have been largely cleared with 
preexisting antibiotics, hence the negative culture results, but 
remaining DNA remnants in the circulation may have been 
sufficient to give a positive PCR/ESI-MS. The sensitivity of the 
technique increases the risk of identifying contaminants and 
commensals; however, the pathogens most frequently detected 
in the study are those associated with infection. Accepting the 
validity of these data, the PCR/ESI-MS test could be of impor-
tance to help target antimicrobial therapy in patients who have 
already started antimicrobials and have negative cultures (sal-
vage microbiology) (29). Further, ideally interventional, studies 
are warranted to confirm and further explore these findings.
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